Reckitt Benckiser Group plc (RBGLY)
| Market Cap | 46.95B -8.9% |
| Revenue (ttm) | 18.09B -3.1% |
| Net Income | 3.82B +115.6% |
| EPS | 1.19 +121.8% |
| Shares Out | n/a |
| PE Ratio | 12.40 |
| Forward PE | 15.78 |
| Dividend | 1.12 (7.56%) |
| Ex-Dividend Date | Aug 10, 2026 |
| Volume | 286,529 |
| Open | 14.89 |
| Previous Close | 15.08 |
| Day's Range | 14.76 - 14.91 |
| 52-Week Range | 12.02 - 17.80 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 15.81 (+6.9%) |
| Est. Earnings | Nov 6, 2026 |
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under... [Read more]
Financial Performance
In 2025, Reckitt Benckiser Group's revenue was 14.21 billion, an increase of 0.25% compared to the previous year's 14.17 billion. Earnings were 3.18 billion, an increase of 123.14%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RBGLY stock is "Buy." The 12-month stock price target is $15.81, which is an increase of 6.90% from the latest price.
News
Reckitt Benckiser price target raised to 7,660 GBp from 7,600 GBp at UBS
UBS analyst Guillaume Delmas raised the firm’s price target on Reckitt Benckiser (RBGLY) to 7,660 GBp from 7,600 GBp and keeps a Buy rating on the shares. Published first on…
FTSE 100 Retreats On Earnings Misses, Shop Price Inflation Surge
(RTTNews) - The U.K. stock market's benchmark index FTSE 100 fell on Tuesday as disappointing earnings from HSBC Holdings and Reckitt Benckiser hurt sentiment. A sharp increase in UK shop price inflat...
Reckitt Benckiser Group Q3 Earnings Call Highlights
Reckitt Benckiser Group LON: RKT reported 3.3% like-for-like net revenue growth in the third quarter, or 3.9% excluding Russia Hygiene, as strength in emerging markets and a return to growth in Europe...
Reckitt Benckiser Group Earnings Call Transcript: Q3 2026
Q3 core revenue grew 3.3%, led by Emerging Markets and a European recovery, while North America was held back by Lysol supply constraints. FY2026 growth guidance is 3.5%-4.5%, with early seasonal demand improving.
Reckitt Benckiser Group Earnings release: Q3 2026
Reckitt Benckiser Group released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Reckitt Cuts Outlook After Lysol Issues Stunt North America Sales
Like-for-like net revenue in North America fell 1.3%, but the company anticipates a rebound from Lysol and North America in the fourth quarter.
Reckitt lowers annual revenue growth guidance on struggles in North America
Dettol maker Reckitt lowered its annual revenue forecast on Tuesday and reported revenue growth below analyst expectations in the third quarter, hampered by a challenging consumer environment
How a Western Consumer Giant Is Thriving on China's Social-Media Shoppers
A change in Reckitt's sales tactics led to 12 consecutive quarters of double-digit sales growth in the country.
Reckitt Benckiser upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded Reckitt Benckiser (RBGLY) to Buy from Neutral with a price target of 6,500 GBp, up from 5,600 GBp. Current share levels offer an attractive entry point into…
Reckitt Benckiser price target lowered to 5,900 GBp from 6,100 GBp at Jefferies
Jefferies lowered the firm’s price target on Reckitt Benckiser (RBGLY) to 5,900 GBp from 6,100 GBp and keeps a Buy rating on the shares ahead of its Q3 results. A…
Lysol and Mucinex Maker Reckitt Expands U.S. Manufacturing
The maker of Lysol and Mucinex is doubling down on U.S. manufacturing and product development, the WSJ Logistics Report's Liz Young writes. Consumer-goods seller Reckitt Benckiser Group says it plans ...
Reckitt Benckiser to invest $400M more in U.S. over four years, WSJ reports
Mucinex and Lysol maker Reckitt Benckiser (RBGLY) plans to invest about $400M more over the next four years in the U.S. to speed up product innovation and demand response, The…
Mucinex Maker Bets $400 Million More on U.S. Supply Chain
Reckitt expands a North Carolina manufacturing plant and a New Jersey campus to meet shifts in consumer demand.
Reckitt Benckiser Group Transcript: Barclays 19th Annual Global Consumer Conference
Management highlighted strong legal wins, robust innovation, and high single-digit growth in emerging markets. Pricing actions are landing well in developing markets, while Europe and the U.S. remain challenging. Mead Johnson continues to attract interest, and operational efficiency is improving through cost initiatives.
Reckitt Benckiser downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas downgraded Reckitt Benckiser (RBGLY) to Neutral from Outperform with a 5,800 GBp price target
Reckitt Benckiser upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Reckitt Benckiser (RBGLY) to Overweight from Neutral with a price target of 6,500 GBp, up from 5,800 GBp. The firm believes the company is closer to settling its…
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
Reckitt Benckiser’s Mead Johnson faces first bellwether trial over Enfamil
Reckitt Benckiser (RBGLY) subsidiary, Mead Johnson is facing the first bellwether as part of a multidistrict litigation in the US District Court for the Northern District of Illinois over its…
First Bellwether Trial Today Against Reckitt Benckiser's Mead Johnson in NEC Baby Formula MDL Led by Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--Reckitt Benckiser (LON: RKT) subsidiary, Mead Johnson is facing the first bellwether today as part of a multidistrict litigation (MDL) in the US District Court for th...
Reckitt Announces Expiration and Results of Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Company Notes due 2044
SLOUGH, United Kingdom, Aug. 14, 2026 /PRNewswire/ -- Reckitt Benckiser Group plc ("Reckitt") (LSE: RKT) announced today (i) the expiration and results of its wholly-owned subsidiary, Mead Johnson Nut...
Reckitt Benckiser Group H1 Earnings Call Highlights
Reckitt Benckiser Group LON: RKT reported accelerating sales growth in the second quarter of 2026, supported by innovation, emerging-market demand and a return to growth in North America, while mainta...
Reckitt Benckiser Group Earnings Call Transcript: H1 2026
Group delivered 2.6% like-for-like net revenue growth in H1 2026, with Q2 accelerating to 4.7%. Innovation, emerging markets, and portfolio focus drove performance, while over GBP 3 billion was returned to shareholders. Full-year guidance for 4%-5% growth and margin targets remain unchanged.
Reckitt Benckiser Group Quarterly report: H1 2026
Reckitt Benckiser Group has published its H1 2026 quarterly earnings report on July 29, 2026.
Reckitt Benckiser Group Slides: H1 2026
Reckitt Benckiser Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 29, 2026.
Lysol Maker Reckitt Issues New $664 Million Share Buyback
The Lysol, Mucinex and Durex-condom maker issued a new share buyback program after reporting 4.7% like-for-like net revenue, bolstered by growth in emerging markets.